Mariam Rojas
YOU?
Author Swipe
View article: Metabolic plasticity drives specific mechanisms of chemotherapy and targeted therapy resistance in metastatic colorectal cancer
Metabolic plasticity drives specific mechanisms of chemotherapy and targeted therapy resistance in metastatic colorectal cancer Open
Microsatellite-stable metastatic colorectal cancer (MSS mCRC) is currently treated with chemotherapy and targeted agents based on RAS and BRAF mutational status. Although these therapies offer initial benefit, most patients rapidly develop…
View article: Metabolic plasticity underlying resistance to anti-PD1 retifanlimab and the arginase inhibitor CB-1158, in microsatellite-stable colorectal cancer patient-derived organoids co-cultured with tumor-infiltrating lymphocytes
Metabolic plasticity underlying resistance to anti-PD1 retifanlimab and the arginase inhibitor CB-1158, in microsatellite-stable colorectal cancer patient-derived organoids co-cultured with tumor-infiltrating lymphocytes Open
Aim Cancer immunotherapies show low activity in metastatic microsatellite-stable (MSS) colorectal cancer (CCR) patients. Arginase 1 inhibitors have shown activity in pre-clinical animal models associated with PD-1 inhibitors but failed in …
View article: Current efficacy of immune checkpoint inhibitors in microsatellite unstable colorectal cancer and potential biomarkers
Current efficacy of immune checkpoint inhibitors in microsatellite unstable colorectal cancer and potential biomarkers Open
Microsatellite unstable (MSI) colorectal cancer (CRC) tumors have a high mutational load (particularly frame-shift mutations) that creates numerous neoantigens that are presented to major histocompatibility complex molecules and recognized…
View article: Metabolic Singularities in Microsatellite-Stable Colorectal Cancer: Identifying Key Players in Immunosuppression to Improve the Immunotherapy Response
Metabolic Singularities in Microsatellite-Stable Colorectal Cancer: Identifying Key Players in Immunosuppression to Improve the Immunotherapy Response Open
Although immune checkpoint inhibitor (ICI) therapy is currently the standard of care in microsatellite-unstable (MSI) metastatic colorectal cancer (CRC), ICI therapy, alone or in combination with other therapies, is not a treatment approac…
View article: Retifanlimab and the arginase inhibitor CB-1158 show low activity in microsatellite-stable colorectal cancer patient-derived organoids co-cultured with tumor-infiltrating lymphocytes
Retifanlimab and the arginase inhibitor CB-1158 show low activity in microsatellite-stable colorectal cancer patient-derived organoids co-cultured with tumor-infiltrating lymphocytes Open
Background Cancer immunotherapies show low activity in metastatic microsatellite-stable (MSS) colorectal cancer (CCR) patients. Arginase 1 inhibitors have shown activity in pre-clinical models associated with PD-1 inhibitors. Methods We es…